Linden Advisors’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Linden Advisors’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,115	Closed	-$10.2K	–	563
2022 Q4	$10.2K	Hold	40,115	–	–	﹤0.01%	497
2022 Q3	$3K	Hold	40,115	–	–	﹤0.01%	686
2022 Q2	$4K	Hold	40,115	–	–	﹤0.01%	721
2022 Q1	$9K	Sell	40,115 -165	-0.4%	-$77	﹤0.01%	717
2021 Q4	$22K	Sell	40,280 -25,026	-38%	-$16K	﹤0.01%	721
2021 Q3	$39K	Sell	65,306 -100,693	-61%	-$78.4K	﹤0.01%	632
2021 Q2	$165K	Buy	+165,999	New	+$154K	﹤0.01%	712

Linden Advisors's EBACW Position: Q1 2023 in Review

Linden Advisors sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 40,115 shares — an estimated $10.2K sold.

Linden Advisors first reported a position in EBACW in Q2 2021 and held it in 7 quarters. The position peaked at $165K in Q2 2021. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

Linden Advisors reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
Linden Advisors sold 40,115 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $10.2K.
Linden Advisors first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 7 quarters.
Linden Advisors's European Biotech Acquisition Corp. Warrant position peaked at $165K in Q2 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Linden Advisors's 13F filing for Q1 2023, filed 15 May 2023.